Altamira Therapeutics Ltd. Diluted Earnings Loss Per Share From Continuing Operations
Altamira Therapeutics Ltd. (CYTOF) reported Diluted Earnings Loss Per Share From Continuing Operations of -$0.31 per share for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-29.
Financial Statements › Income Statement › Earnings Per Share
ifrs-full:DilutedEarningsLossPerShareFromContinuingOperations · last filed 2025-08-29
CHF/shares
| Period end | Diluted Earnings Loss Per Share From Continuing Operations 12 month |
|---|---|
| 2023-12-31 | -14.80 CHF/shares 20-F/A · filed 2024-04-22 |
| 2022-12-31 | -409.60 CHF/shares 20-F/A · filed 2024-04-22 |
| 2021-12-31 | -201.97 CHF/shares 20-F/A · filed 2024-04-22 |
USD/shares
| Period end | Diluted Earnings Loss Per Share From Continuing Operations 6 month | Diluted Earnings Loss Per Share From Continuing Operations 12 month |
|---|---|---|
| 2025-06-30 | -$0.31 6-K · filed 2025-08-29 | |
| 2024-12-31 | -$2.99 20-F · filed 2025-04-30 | |
| 2024-06-30 | -$2.11 6-K · filed 2025-08-29 | |
| 2023-12-31 | -$16.47 20-F · filed 2025-04-30 | |
| 2023-06-30 | -$21.55 6-K · filed 2024-09-24 | |
| 2022-12-31 | -$428.90 20-F · filed 2025-04-30 |